XIGRIS Pages on BioPortfolio:

Eli Lilly's Xigris: struggling to overcome its problems in the ...
28 Feb 2002 ... The once lauded drug Xigris is struggling to recover from a series of ... Lilly's explanation for Xigris' stuttering start was possibly too ...
http://www.bioportfolio.com/news/datamonitor_29.htm...

Biotechnology News XIGRIS Search
Documents 1-13 out of 13 found. Current Search: xigris: 13 ... News-Medical.Net: Nov 6 2009 7:13AM Matching: xigris, Find similar documents ...
http://www.bioportfolio.co.uk/XIGRIS-news.htm...

BioPortfolio - Xigris
Xigris - BioPortfolio - Indepth. ... Xigris. Drotrecogin Alfa. Download PDF containing detailed information. PDF Version ...
http://www.bioportfolio.com/indepth/Xigris.html...

BioPortfolio Bulletin: Biotechnology Strategic Intelligence and ...
Lilly's Xigris is profiled with projections for future performance. For further information go to: ...
http://www.bioportfolio.co.uk/bulletin_29.htm...

Biotech Tracker News - Pafase Fails Sepsis Trials
Although initial sales of Xigris have been slow, Eli Lilly has time to solidify ... Numerous Xigris trials designed to address clinical and commercial ...
http://www.bioportfolio.com/news/biotracker_46.htm...

BioPortfolio.com - BioWeb ZENAPAX DACLIZUMAB Search
Karl Thomae GmbH Birkendorfter Strasse 65 88397 Biberach/Riss GERMANY License 1199 08/20/1996 Xigris Drotrecogin alfa (activated) Reduction of mortality in
...
http://www.bioportfolio.co.uk/ZENAPAX+DACLIZUMAB-bioweb.htm...

BioPortfolio - Protherics
Eli Lilly's Xigris: struggling to overcome its problems in the sepsis market The once lauded drug Xigris is struggling to recover from ...
http://www.bioportfolio.com/biocorporate/8617-Protherics.htm...

BioPortfolio Bulletin - November 19 2002
Eli Lilly's Xigris: struggling to overcome its problems in the sepsis market · Hepatocellular carcinoma: pointing the way for other niche cancers ...
http://www.bioportfolio.co.uk/bulletin_11.htm...

BioPortfolio Limited Clinical Forecasting A Novel Bayesian Tool ...
The author includes a retrospective case study demonstrating the application of Bayesian clinical forecasting to Eli Lilly's Xigris (recombinant human ...
http://www.bioportfolio.com/cgi-bin/acatalog/Clinical_Foreca...

BioPortfolio.com - BioWeb PROSTASCINT CAPROMAB PENDETIDE Search
... License 1579 MYOBLOC Botulinum Toxin Type B 103846/0 12/8/2000 5000 IU/mL Eli Lilly & Company License 1611 Xigris Drotrecogin alfa (Activated. ...
http://www.bioportfolio.co.uk/PROSTASCINT+CAPROMAB+PENDETIDE...

Results from other life science and pharmaceutical sites:

Drotrecogin alfa - Wikipedia, the free encyclopedia
10 Oct 2009 ... Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has ...
http://en.wikipedia.org/wiki/Drotrecogin_alfa...

Eli Lilly and Company » Xigris® Media Kit
We are pleased to provide you with this resource on Xigris®. By providing you with this extensive online guide, our goal is to help you tell the story about
...
http://www.lilly.com/news/kits/xigris/...

Controversy Brews Over Xigris' Role in Treating Sepsis
1 Oct 2002 ... Some experts believe that the data are encouraging but insufficient for standard of care, while Lilly and the FDA justify their positions.
http://www.medscape.com/viewarticle/442255...

Early Communication about an Ongoing Safety Review Xigris ...
18 Jun 2009 ... Early Communication about an Ongoing Safety Review Xigris (Drotrecogin alfa [ activated])
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...

Important Safety Information on Xigris
Xigris is approved for the reduction of mortality in adult patients with severe ... The efficacy of Xigris has not been established in adult patients with ...
http://www.lilly.com/pdf/xigris_safety_information.pdf...

Xigris [drotrecogin alfa (activated)] Discontinuation of Study
19 Jun 2009 ... Eli Lilly and FDA notified healthcare professionals of the stopping of enrollment in a randomized, double-blind, placebo-controlled trial of ...
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyA...

Activated protein C (Xigris) treatment in sepsis: a drug in trouble.
Activated protein C (Xigris) treatment in sepsis: a drug in trouble. Gårdlund B. Department of Infectious Diseases, Karolinska University Hospital Huddinge, ...
http://www.ncbi.nlm.nih.gov/pubmed/16923083...

Xigris (Drotrecogin alfa [activated]) - Early Communication about ...
4 Feb 2009 ... The finding by Gentry et al. of an increased risk of death and serious bleeding events in patients treated with Xigris who also have ...
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyA...

FDA Continues to Investigate Bleeding Risk for Xigris
4 Feb 2009 ... The Food and Drug Administration announced today that is continuing to evaluate the incidence of serious bleeding events and death in ...
http://www.medscape.com/viewarticle/587847...

Xigris [drotrecogin alfa (activated)] Mar 2005
19 Jun 2009 ... Eli Lilly and FDA notified healthcare professionals about revisions to the WARNINGS section of labeling for Xigris [drotrecogin alfa ...
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyA...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.